Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans
Elevated plasma IL-18 is present in several conditions sharing insulin-resistance as common trait, but the association with insulin-resistance per se is not established. Plasma/serum IL-6, IL-18, TNF-α, soluble TNF receptor II (sTNFR2), and C-reactive protein (CRP) were measured in 97 patients with...
Gespeichert in:
| Veröffentlicht in: | Clinical Immunology Jg. 117; H. 2; S. 152 - 160 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
San Diego, CA
Elsevier Inc
01.11.2005
Elsevier |
| Schlagworte: | |
| ISSN: | 1521-6616, 1521-7035, 1365-2567 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | Elevated plasma IL-18 is present in several conditions sharing insulin-resistance as common trait, but the association with insulin-resistance per se is not established. Plasma/serum IL-6, IL-18, TNF-α, soluble TNF receptor II (sTNFR2), and C-reactive protein (CRP) were measured in 97 patients with type 2 diabetes (DM) and 84 non-diabetic controls (CON). The association with insulin-resistance—estimated using the homeostasis model assessment (HOMA-IR)—was analyzed using multivariate linear and logistic regression. Compared to CON, DM demonstrated higher plasma levels of IL-18 (
P = 0.001), IL-6 (
P < 0.001), sTNFR2 (
P = 0.005), and CRP (
P < 0.001), while TNF-α was lower (
P = 0.017). Plasma IL-18 increased across HOMA-IR quartiles in both DM and CON, both with and without adjustment for confounders (all
P < 0.05). In contrast, neither IL-6, TNF-α, sTNFR2, nor CRP was associated with HOMA-IR in CON when adjusting for confounders. Accordingly, 50% increase of IL-18 corresponded to a marked increase of HOMA-IR in both DM and CON (DM: 26%,
P = 0.014; CON: 25%,
P = 0.003) after adjustment for confounders. Our results show that plasma IL-18 was associated with HOMA-IR independent of obesity and type 2 diabetes. |
|---|---|
| Bibliographie: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| ISSN: | 1521-6616 1521-7035 1365-2567 |
| DOI: | 10.1016/j.clim.2005.07.008 |